CAPRICOR THERAPEUTICS, INC. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 62/100
What the filing says
Capricor Therapeutics executed a lease on July 9, 2026 for the entire 171,001 sq ft building at 9625 Towne Centre Drive, San Diego (ARE-SD Region No. 39 Owner, LLC). Base rent: $67.20/sq ft/year (~$11.5M annually); 138-month base term; 18-month base rent abatement, then 6-month partial abatement (43,453 sq ft) before full rent kicks in. Security deposit: $957,606 (letter of credit). Tenant responsible for 100% operating expenses, utilities, janitorial, building system maintenance (HVAC, plumbing, fire systems, elevators). Landlord provides $5.13M tenant improvement allowance ($30/sq ft). Two 5-year renewal options at market rate. Lease contingent on Environmental Permits; either party may terminate if permits not obtained by end of 2026.
Why this rating
Real estate commitment material to ~$399M biotech company: ~$11.5M/year base rent (3% inflation) plus operating costs = significant recurring liability (~8–10% of likely revenue scale). 138-month term locks in strategy and real estate risk. Rent abatement and TI allowance favor Tenant. Operational upside: purpose-built life science facility supports manufacturing/R&D scale. Neutral-to-modest risk; manageable for public biotech but meaningful capital deployment.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.